SummitTX Capital L.P. Grows Position in Phibro Animal Health Corporation $PAHC

SummitTX Capital L.P. lifted its position in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 113.4% during the 1st quarter, HoldingsChannel reports. The firm owned 75,466 shares of the company’s stock after acquiring an additional 40,102 shares during the period. SummitTX Capital L.P.’s holdings in Phibro Animal Health were worth $4,174,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its holdings in Phibro Animal Health by 1,730.9% in the third quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock worth $9,634,000 after purchasing an additional 225,110 shares in the last quarter. Advisors Preferred LLC bought a new stake in shares of Phibro Animal Health during the 1st quarter valued at $2,931,000. Cvfg LLC bought a new stake in shares of Phibro Animal Health during the 1st quarter valued at $2,962,000. Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in shares of Phibro Animal Health in the 1st quarter worth about $1,759,000. Finally, Precision Wealth Strategies LLC purchased a new stake in shares of Phibro Animal Health in the 4th quarter worth about $1,568,000. 99.34% of the stock is owned by hedge funds and other institutional investors.

Phibro Animal Health Trading Up 3.6%

Shares of NASDAQ PAHC opened at $35.24 on Tuesday. The firm’s 50 day moving average price is $32.47 and its 200-day moving average price is $43.26. Phibro Animal Health Corporation has a 52-week low of $25.58 and a 52-week high of $60.08. The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.26 and a current ratio of 3.17. The company has a market cap of $1.43 billion, a PE ratio of 15.12, a P/E/G ratio of 0.48 and a beta of 0.46.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The company had revenue of $383.54 million during the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. On average, equities research analysts expect that Phibro Animal Health Corporation will post 3.08 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 24th. Shareholders of record on Wednesday, June 3rd were paid a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 1.4%. The ex-dividend date was Wednesday, June 3rd. Phibro Animal Health’s dividend payout ratio (DPR) is currently 20.60%.

Insider Activity at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 4,528 shares of Phibro Animal Health stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $48.49, for a total value of $219,562.72. Following the completion of the sale, the chief executive officer owned 56,152 shares of the company’s stock, valued at approximately $2,722,810.48. This trade represents a 7.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 18,608 shares of company stock valued at $983,825. 50.13% of the stock is currently owned by company insiders.

Analyst Ratings Changes

PAHC has been the subject of several research reports. Weiss Ratings lowered shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, June 15th. Zacks Research lowered shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 21st. Citigroup cut their price objective on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a report on Thursday, May 14th. Finally, Wall Street Zen downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. One analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $42.50.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.